Loading stock data…
Merck & Company, Inc. (MRK)
$129.30+0.64 (+0.50%)
Market OpenUpdated 3:19 PM EDT
Merck & Co., Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck & Co., Inc. in the Healthcare sector is trading at $128.57 with a market capitalization of $285.2B. Wall Street consensus targets $130.39 (28 analysts), implying a +1.4% move over the next 12 months. The stock is currently near its 52-week high of $129.09, remaining 22.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.29B↓ | $16.40B↓ | $17.28B↑ | $15.81B↑ | $15.53B |
| Gross Profit | $12.09B↑ | $10.85B↓ | $13.42B↑ | $12.25B↑ | $12.11B |
| Operating Income | -$3.20B↓ | $4.07B↓ | $6.55B↑ | $5.55B↓ | $5.94B |
| Net Income | -$4.24B↓ | $2.96B↓ | $5.79B↑ | $4.43B↓ | $5.08B |
Peer Comparison
JNJUNHPFE
Fundamentals
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bri...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$285.22B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.53
Beta
Defensive asset. Lower volatility than the S&P 500.
0.22
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.60%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.48%
Volume
Today's trading volume
5.39M
Recent News
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Stock futures rise as U.S. and Iran agree to stop latest attacks
A weekend of back-and-forth military exchanges between Washington and Tehran had put broader peace negotiations at risk
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]